Project
A first-in-human, open-label, multicenter Phase l/ll study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with advanced solid tumors (EXPAND-1)
Ongoing - recruitment active · 2024 until 2028
Jörger Markus, Sennhauser Andrina, Müller Fiona
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2024
End Date
2028
Financing
Industry
Labels
pancreatic cancer